Fineotex Chemical Reports Strong Q4 FY26 Results

Fineotex Chemical Limited announced a significant surge in its Q4 FY26 financial results, with consolidated revenue jumping 161.91% year-on-year to ₹313.73 crore. The company’s consolidated Profit After Tax (PAT) for the quarter rose by 117.56% to ₹43.80 crore. These audited results for the quarter and full financial year ended March 31, 2026, were approved by the Board of Directors on May 15, 2026.

For the full fiscal year 2026, Fineotex Chemical’s consolidated revenue reached approximately ₹772.23 crore, marking a 44.79% increase from the previous year. Consolidated PAT for FY26 was approximately ₹125.01 crore, up 14.50% year-on-year.

The company's Board also recommended a final dividend of ₹0.05 per equity share. This dividend is subject to shareholder approval at the upcoming Annual General Meeting. This recommendation brings the total dividend payout for the fiscal year 2025-26 to ₹14.99 crore.

Strong Revenue Growth Drivers

The substantial revenue growth in Q4 FY26 suggests strong operational expansion, successful market penetration, or the impact of new production capacities coming online, outpacing broader industry trends. However, the PAT growth, while robust, did not match the revenue expansion. This indicates potential margin pressures or significant non-operating expenses that affected profitability.

Financial Impact from Past Events

Fineotex Chemical's financial statements for the period reflect costs associated with past corporate actions. This includes the forfeiture of ₹2,242.12 lakh (₹22.42 crore) due to 23,15,049 warrants, originally issued to the promoter group in May 2023 and convertible within 18 months, not being exercised by their holders.

Additionally, a legal dispute concerning an assignment agreement for a property classified under assets held for sale has been settled. The company paid ₹617.68 lakh to resolve this matter, which concluded after the financial year-end. An MOU for property transfer and an advance received are also noted.

Peer Performance and Key Metrics

Fineotex Chemical's Q4 FY26 revenue surge of 161.91% significantly outpaced competitors. For comparison, peers like Rossari Biotech reported approximately 18% revenue growth for FY26, and S P Chemicals saw about 8% growth in the same period.

While Fineotex's top-line momentum is exceptional, its PAT growth of 117.56% in Q4 lagged its revenue expansion, a trend less pronounced in the reported peer financials, suggesting company-specific factors were at play.

The company was also recognized as a "Great Place to Work®" for five consecutive years, indicating a stable work environment. Key metrics for the year ended March 31, 2026, include a consolidated Return on Invested Capital (ROIC) of 31.10%.

Investors will be watching for shareholder approval of the final dividend, accounting implications from the property transfer MOU, management's commentary on sustaining Q4 revenue growth and margin drivers in the next earnings call, and updates on the utilization of the ₹800 lakh advance received for the property.